170 related articles for article (PubMed ID: 33657894)
1. Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy.
Riva I; Micheletti E; Fausto R; Bruttini C; De Angelis G; Ceccuzzi R; Quaranta L
Eur J Ophthalmol; 2022 Jul; 32(4):NP78-NP81. PubMed ID: 33657894
[TBL] [Abstract][Full Text] [Related]
2. Topical cenegermin 0.002% for pediatric neurotrophic keratopathy.
Elhusseiny AM; Traish AS; Saeed HN; Mantagos IS
Eur J Ophthalmol; 2022 Nov; 32(6):3420-3424. PubMed ID: 35469461
[TBL] [Abstract][Full Text] [Related]
3. Successful Treatment of a Pediatric Neurotrophic Keratopathy With Cenegermin.
Papadopoulos K; Besgen V; Sekundo W
Cornea; 2021 Apr; 40(4):516-518. PubMed ID: 32947402
[TBL] [Abstract][Full Text] [Related]
4. A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops.
Fausto R; Ceccuzzi R; Micheletti E; Clerici R; Riva I; Katsanos A; Oddone F; Quaranta L
Medicine (Baltimore); 2020 Jul; 99(30):e20816. PubMed ID: 32791670
[TBL] [Abstract][Full Text] [Related]
5. Acute Calcific Band Keratopathy as an Adverse Effect of Recombinant Human Nerve Growth Factor (Cenegermin): A Multicenter Case Series.
Qureshi S; Ferguson TJ; Lim M; You JY; Goshe JM; Hood CT
Cornea; 2022 Jan; 41(1):52-59. PubMed ID: 34582138
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical outcome and satisfaction survey in patients with neurotrophic keratopathy after treatment with cenegermin eye drops or amniotic membrane transplantation.
Sacchetti M; Komaiha C; Bruscolini A; Albanese GM; Marenco M; Colabelli Gisoldi RAM; Pocobelli A; Lambiase A
Graefes Arch Clin Exp Ophthalmol; 2022 Mar; 260(3):917-925. PubMed ID: 34633522
[TBL] [Abstract][Full Text] [Related]
7. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.
Pflugfelder SC; Massaro-Giordano M; Perez VL; Hamrah P; Deng SX; Espandar L; Foster CS; Affeldt J; Seedor JA; Afshari NA; Chao W; Allegretti M; Mantelli F; Dana R
Ophthalmology; 2020 Jan; 127(1):14-26. PubMed ID: 31585826
[TBL] [Abstract][Full Text] [Related]
8. Cenegermin in Pediatric Neurotrophic Keratopathy.
Pedrotti E; Bonetto J; Cozzini T; Fasolo A; Marchini G
Cornea; 2019 Nov; 38(11):1450-1452. PubMed ID: 31403527
[TBL] [Abstract][Full Text] [Related]
9. Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy.
Pedrotti E; Bonacci E; Chierego C; De Gregorio A; Cozzini T; Brighenti T; Caldarella G; Pastore G; Fasolo A; Marchini G
Orphanet J Rare Dis; 2022 Feb; 17(1):63. PubMed ID: 35189948
[TBL] [Abstract][Full Text] [Related]
10. Cenegermin for the treatment of neurotrophic keratitis.
Sacchetti M; Bruscolini A; Lambiase A
Drugs Today (Barc); 2017 Nov; 53(11):585-595. PubMed ID: 29451275
[TBL] [Abstract][Full Text] [Related]
11. Clinical and instrumental assessment of the corneal healing in moderate and severe neurotrophic keratopathy treated with rh-NGF (Cenegermin).
Roszkowska AM; Inferrera L; Aragona E; Gargano R; Postorino EI; Aragona P
Eur J Ophthalmol; 2022 Nov; 32(6):3402-3410. PubMed ID: 35473440
[TBL] [Abstract][Full Text] [Related]
12. Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?
Bruscolini A; Marenco M; Albanese GM; Lambiase A; Sacchetti M
Orphanet J Rare Dis; 2022 Feb; 17(1):57. PubMed ID: 35172847
[TBL] [Abstract][Full Text] [Related]
13. Cenegermin: A Review in Neurotrophic Keratitis.
Deeks ED; Lamb YN
Drugs; 2020 Apr; 80(5):489-494. PubMed ID: 32185680
[TBL] [Abstract][Full Text] [Related]
14. Aftermarket effects of cenegermin for neurotrophic keratopathy in pediatric patients.
Hatcher JB; Soifer M; Morales NG; Farooq AV; Perez VL; Shieh C
Ocul Surf; 2021 Jul; 21():52-57. PubMed ID: 33887453
[TBL] [Abstract][Full Text] [Related]
15. Real Life Data on Efficacy and Safety of Topical NGF Eye Drops (Cenegermin).
Zwingelberg SB; Bachmann BO; Cursiefen C
Klin Monbl Augenheilkd; 2020 Dec; 237(12):1455-1461. PubMed ID: 33285589
[TBL] [Abstract][Full Text] [Related]
16. Pediatric Use of Recombinant Human Nerve Growth Factor 20 μg/mL Eye Drops (Cenegermin) for Bilateral Neurotrophic Keratopathy in Congenital Corneal Anesthesia.
Leto MG; Toro ME; Indemini PE; Fruttero C; Denina M; Dalmazzo C; Sannia A; Vaiano AS
Cornea; 2021 Feb; 40(2):228-231. PubMed ID: 33201057
[TBL] [Abstract][Full Text] [Related]
17. Neurotrophic keratopathy: Clinical presentation and effects of cenegermin.
Bu JB; Gericke A; Pfeiffer N; Wasielica-Poslednik J
Am J Ophthalmol Case Rep; 2022 Jun; 26():101488. PubMed ID: 35330588
[TBL] [Abstract][Full Text] [Related]
18. Cutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy-Biologicals as a Novel Therapy for Neurotrophic Keratopathy.
Hamrah P; Yavuz Saricay L; Ozmen MC
Cornea; 2022 Jun; 41(6):673-679. PubMed ID: 35266655
[TBL] [Abstract][Full Text] [Related]
19. Resolution of a neurotrophic keratopathy associated hypopyon with cenegermin.
Zambino N; Syed ZA
Am J Ophthalmol Case Rep; 2021 Sep; 23():101113. PubMed ID: 34307960
[TBL] [Abstract][Full Text] [Related]
20. A Novel Treatment for Neurotrophic Corneal Ulcer Using Topical Cenegermin (OXERVATE™) Containing Recombinant Human Nerve Growth Factor.
Ahuja AS; Bowden FW; Robben JL
Cureus; 2020 Nov; 12(11):e11724. PubMed ID: 33391953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
